P. Stopfer

发表

Physiologically Based Pharmacokinetic Modeling of Rosuvastatin to Predict Transporter-Mediated Drug-Drug Interactions

J. D. Gómez-Mantilla, N. Hanke, N. Ishiguro, 2021, Pharmaceutical Research.

A Mechanistic, Enantioselective, Physiologically Based Pharmacokinetic Model of Verapamil and Norverapamil, Built and Evaluated for Drug–Drug Interaction Studies

T. Lehr, D. Selzer, Denise Türk, 2020, Pharmaceutics.

Physiologically Based Pharmacokinetic Models of Probenecid and Furosemide to Predict Transporter Mediated Drug-Drug Interactions

T. Lehr, M. Taub, N. Hanke, 2020, Pharmaceutical Research.

Validation of a Drug Transporter Probe Cocktail Using the Prototypical Inhibitors Rifampin, Probenecid, Verapamil, and Cimetidine

F. Müller, M. Fromm, K. Hohl, 2020, Clinical Pharmacokinetics.

A Comprehensive Whole-Body Physiologically Based Pharmacokinetic Drug–Drug–Gene Interaction Model of Metformin and Cimetidine in Healthy Adults and Renally Impaired Individuals

F. Müller, T. Lehr, D. Selzer, 2020, Clinical Pharmacokinetics.

Optimization of a drug transporter probe cocktail: potential screening tool for transporter‐mediated drug–drug interactions

F. Müller, K. Hohl, M. Taub, 2018, British journal of clinical pharmacology.

A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours

J. Verweij, E. de Vries, J. Gietema, 2007, British Journal of Cancer.

Vascular effects, efficacy and safety of nintedanib in patients with advanced, refractory colorectal cancer: a prospective phase I subanalysis

R. Kaiser, M. Büchert, P. Stopfer, 2014, BMC Cancer.

Pharmacokinetics and metabolism of BIBF 1120 after oral dosing to healthy male volunteers

R. Kaiser, T. Ebner, K. Rathgen, 2011, Xenobiotica; the fate of foreign compounds in biological systems.

Randomized phase II study of nintedanib in metastatic castration-resistant prostate cancer postdocetaxel

R. Kaiser, J. Droz, S. Oudard, 2014, Anti-cancer drugs.

A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer.

R. Kaiser, R. Doebele, D. Camidge, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer.

R. Kaiser, J. von Pawel, U. Gatzemeier, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies.

S. Loibl, J. Huober, P. Harter, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors

J. Marshall, M. Uttenreuther-Fischer, H. Burger, 2012, Investigational New Drugs.

Phase 1 study with BIBW 2992, an irreversible dual tyrosine kinase inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) in a 2 week on 2 week off schedule.

E. D. de Vries, J. Verweij, M. D. de Jonge, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetics of afatinib in subjects with mild or moderate hepatic impairment

M. Uttenreuther-Fischer, A. Halabi, Rainer-Georg Goeldner, 2014, Cancer Chemotherapy and Pharmacology.

Afatinib pharmacokinetics and metabolism after oral administration to healthy male volunteers

T. Ebner, H. Narjes, P. Stopfer, 2012, Cancer Chemotherapy and Pharmacology.

Cells from Mouse Bone Marrow-Derived Mast Activated T Cells Induces Cytokine Release Receptor Activation by β Lymphotoxin -

D. Männel, T. Hehlgans, P. Stopfer, 2004 .

Lymphotoxin-β Receptor Activation by Activated T Cells Induces Cytokine Release from Mouse Bone Marrow-Derived Mast Cells1

D. Männel, T. Hehlgans, P. Stopfer, 2004, The Journal of Immunology.

Blocking lymphotoxin‐β receptor activation diminishes inflammation via reduced mucosal addressin cell adhesion molecule‐1 (MAdCAM‐1) expression and leucocyte margination in chronic DSS‐induced colitis

D. Männel, F. Obermeier, W. Falk, 2004 .

P3-091: A Phase I study of continuous oral treatment with the triple angiokinase inhibitor BIBF 1120 together with pemetrexed in previously treated patients with non-small cell lung cancer

N. Hanna, P. Ellis, D. Shapiro, 2007 .

A phase I dose escalation and pharmacokinetic study of BIBF 1120 in combination with paclitaxel and carboplatin in patients with advanced gynecological malignancies

R. Kaiser, S. Loibl, J. Huober, 2007 .

A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a continuous schedule in patients with advanced solid tumours.

D. Agus, M. Gordon, P. Stopfer, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I dose escalation study of BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in a 3 week on 1 week off schedule in patients with advanced solid tumors.

J. Marshall, R. Cohen, N. Lewis, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetic results from two phase I dose escalation studies of once daily oral treatment with BIBW 2992, an irreversible dual EGFR/HER2 receptor tyrosine kinase inhibitor, in patients with advanced solid tumors.

J. Verweij, J. Marshall, J. Gietema, 2005 .

Population pharmacokinetics of afatinib, an irreversible ErbB family blocker, in patients with various solid tumors

A. Staab, U. Schmid, M. Freiwald, 2014, Cancer Chemotherapy and Pharmacology.

Pharmacokinetic Properties of Nintedanib in Healthy Volunteers and Patients With Advanced Cancer

R. Kaiser, D. Trommeshauser, P. Stopfer, 2016, Journal of clinical pharmacology.

Pharmacokinetics of Afatinib, a Selective Irreversible ErbB Family Blocker, in Patients with Advanced Solid Tumours

Rainer-Georg Goeldner, P. Stopfer, S. Wind, 2013, Clinical Pharmacokinetics.

Phase I study of nintedanib incorporating dynamic contrast-enhanced magnetic resonance imaging in patients with advanced solid tumors.

D. Collins, A. Padhani, D. Koh, 2015, The oncologist.

Blocking lymphotoxin beta receptor signalling exacerbates acute DSS-induced intestinal inflammation--opposite functions for surface lymphotoxin expressed by T and B lymphocytes.

D. Männel, F. Bataille, S. Nedospasov, 2008, Molecular immunology.

An open-label dose-escalation study of BIBF 1120 in patients with relapsed or refractory multiple myeloma.

W. Berdel, B. Gaschler-Markefski, J. Kienast, 2009, Anticancer research.

Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib

T. Ebner, U. Schmid, M. Freiwald, 2019, Clinical Pharmacokinetics.

Lymphotoxin-beta receptor immune interaction promotes tumor growth by inducing angiogenesis.

D. Männel, K. Pfeffer, M. Guba, 2002, Cancer research.

Growth by Inducing Angiogenesis Receptor Immune Interaction Promotes Tumor β Lymphotoxin-Updated Version

D. Männel, K. Pfeffer, M. Guba, 2002 .

Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors.

R. Plummer, A. Futreal, M. Uttenreuther-Fischer, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors

M. Piccart, M. Uttenreuther-Fischer, A. Awada, 2012, Investigational New Drugs.

Clinical Pharmacokinetics and Pharmacodynamics of Afatinib

T. Ebner, M. Freiwald, P. Stopfer, 2016, Clinical Pharmacokinetics.

A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors

M. Gross, D. Agus, M. Uttenreuther-Fischer, 2012, Investigational New Drugs.

Phase I dose-escalation study of afatinib, an ErbB family blocker, plus docetaxel in patients with advanced cancer.

G. Shapiro, J. Marshall, M. Uttenreuther-Fischer, 2013, Future oncology.

Lymphotoxin-beta receptor activation by activated T cells induces cytokine release from mouse bone marrow-derived mast cells.

D. Männel, T. Hehlgans, P. Stopfer, 2004, Journal of immunology.

Phase II trial of weekly alternating sequential BIBF 1120 and afatinib for advanced colorectal cancer.

M. Ducreux, O. Bouché, A. de Gramont, 2011, Anticancer research.

Phase I Study of the Angiogenesis Inhibitor BIBF 1120 in Patients with Advanced Solid Tumors

R. Kaiser, C. Unger, Jürgen Henning, 2009, Clinical Cancer Research.

Activation of the lymphotoxin-beta receptor induces NFkappaB-dependent interleukin-6 and MIP-2 secretion in mouse fibrosarcoma cells.

D. Männel, T. Hehlgans, P. Stopfer, 2003, European cytokine network.

Pharmacokinetic Drug Interactions of Afatinib with Rifampicin and Ritonavir

T. Giessmann, P. Stopfer, S. Wind, 2014, Clinical Drug Investigation.

A clinical phase I, pharmacokinetic (PK), and pharmacodynamic study of twice daily BIBF 1120 in advanced cancer patients

Jürgen Hennig, Ralph Strecker, J. Hennig, 2005 .

Treatment of lung cancer patients and concomitant use of drugs interacting with cytochrome P450 isoenzymes.

R. Kaiser, M. Eichelbaum, H. Varker, 2011, Lung cancer.

Phase I Open-Label Study of Continuous Treatment with BIBF 1120, a Triple Angiokinase Inhibitor, and Pemetrexed in Pretreated Non–Small Cell Lung Cancer Patients

N. Hanna, R. Kaiser, P. Ellis, 2010, Clinical Cancer Research.

Effects of Metformin and Furosemide on Rosuvastatin Pharmacokinetics in Healthy Volunteers: Implications for Their Use as Probe Drugs in a Transporter Cocktail

Mitchell E Taub, Fabian Müller, Thomas Ebner, 2017, European Journal of Drug Metabolism and Pharmacokinetics.

Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors

M. Uttenreuther-Fischer, J. Spicer, S. Rudman, 2013, Cancer Chemotherapy and Pharmacology.

A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as ﬁ rst-line treatment in patients with advanced non-small-cell lung cancer

D. Camidge, G. Otterson, A. Traynor, 2022 .

A phase II trial of weekly alternating sequential administration of BIBF1120 and BIBW2992 in patients with advanced colorectal cancer

M. Ducreux, O. Bouché, A. Gramont, 2008 .

Pharmacokinetic Evaluation of a Drug Transporter Cocktail Consisting of Digoxin, Furosemide, Metformin, and Rosuvastatin

F Müller, F. Müller, K. Hohl, 2016, Clinical pharmacology and therapeutics.

Blocking lymphotoxin-beta receptor activation diminishes inflammation via reduced mucosal addressin cell adhesion molecule-1 (MAdCAM-1) expression and leucocyte margination in chronic DSS-induced colitis.

W. Falk, D. Männel, F. Obermeier, 2004, Clinical and experimental immunology.

Effects of Metformin and Furosemide on Rosuvastatin Pharmacokinetics in Healthy Volunteers: Implications for Their Use as Probe Drugs in a Transporter Cocktail

F. Müller, K. Hohl, M. Taub, 2017, European Journal of Drug Metabolism and Pharmacokinetics.

Lymphotoxin-β Rezeptoren Blockade reduziert Leukozyten-Endothelzellen-Interaktion in vivo durch Downregulation von MadCAM-1 bei experimenteller chronischer Kolitis

D. Männel, E. Geissler, H. Schlitt, 2004 .

Pharmacokinetics (PK) of [14C]-BIBW 2992 after administration of a single dose of 15 mg [14C]-BIBW 2992 oral solution in healthy male volunteers

B. Gaschler-Markefski, H. Narjes, P. Stopfer, 2008 .

A phase I dose finding study of the 3-day administration of BIBW 2992, an irreversible dual EGFR/HER-2 inhibitor, in combination with three-weekly docetaxel in patients with advanced solid tumors.

M. Piccart, M. Uttenreuther-Fischer, A. Awada, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pharmacokinetic (PK) analysis of a phase I study of continuous oral treatment with the angiokinase inhibitor BIBF 1120, in combination with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer (NSCLC)

D. Camidge, J. Stephenson, P. Stopfer, 2008 .

704 POSTER A phase I dose escalation and pharmacokinetic study of BIBF 1120, a novel tyrosine kinase inhibitor against VEGFR, PDGFR and FGFR, in combination with docetaxel in advanced chemonaive hormone refractory prostate cancer patients (HRPC)

R. Kaiser, E. Raymond, F. Goldwasser, 2007 .

73 POSTER Pharmacokinetic characterization of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) in advanced cancer patients

R. Kaiser, I. Judson, J. Kienast, 2006 .

Randomized phase II study of nintedanib in metastatic castration-resistant prostate cancer postdocetaxel

R. Kaiser, J. Droz, S. Oudard, 2014, Anti-cancer drugs.

1243 Phase I dose-escalation study of continuous oral treatment with the angiokinase inhibitor BIBF 1120 in patients with advanced solid tumors

R. Kaiser, K. Nishio, T. Satoh, 2009 .

N1‐Methylnicotinamide as Biomarker for MATE‐Mediated Renal Drug–Drug Interactions: Impact of Cimetidine, Rifampin, Verapamil, and Probenecid

F. Müller, M. Fromm, K. Hohl, 2023, Clinical pharmacology and therapeutics.

A Metabolomic Analysis of Sensitivity and Specificity of 23 Previously Proposed Biomarkers for Renal Transporter‐Mediated Drug‐Drug Interactions

F. Müller, M. Fromm, J. König, 2023, Clinical pharmacology and therapy.

New Biomarkers for Renal Transporter-Mediated Drug-Drug Interactions: Metabolomic Effects of Cimetidine, Probenecid, Verapamil, and Rifampin in Humans.

F. Müller, P. Stopfer, A. Gessner, 2024, Clinical pharmacology and therapeutics.

Human Dose and Pharmacokinetic Predictions for Biologics at Boehringer Ingelheim: A Retrospective Analysis

P. Stopfer, Minu R. Pilvankar, J. Ahlberg, 2023, Advances in therapy.